AU2015301014B2 - Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors - Google Patents

Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors Download PDF

Info

Publication number
AU2015301014B2
AU2015301014B2 AU2015301014A AU2015301014A AU2015301014B2 AU 2015301014 B2 AU2015301014 B2 AU 2015301014B2 AU 2015301014 A AU2015301014 A AU 2015301014A AU 2015301014 A AU2015301014 A AU 2015301014A AU 2015301014 B2 AU2015301014 B2 AU 2015301014B2
Authority
AU
Australia
Prior art keywords
oxygen
tumor
various embodiments
polymersomes
myoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301014A
Other languages
English (en)
Other versions
AU2015301014A1 (en
Inventor
P. Peter Ghoroghchian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poseida Therapeutics Inc
Original Assignee
Poseida Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/455,082 external-priority patent/US20140363496A1/en
Application filed by Poseida Therapeutics Inc filed Critical Poseida Therapeutics Inc
Publication of AU2015301014A1 publication Critical patent/AU2015301014A1/en
Assigned to POSEIDA THERAPEUTICS, INC. reassignment POSEIDA THERAPEUTICS, INC. Request for Assignment Assignors: VINDICO NANOBIOTECHNOLOGY, LLC
Application granted granted Critical
Publication of AU2015301014B2 publication Critical patent/AU2015301014B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Nanotechnology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015301014A 2014-08-08 2015-08-06 Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors Active AU2015301014B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/455,082 2014-08-08
US14/455,082 US20140363496A1 (en) 2011-01-07 2014-08-08 Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
PCT/US2015/044017 WO2016022805A1 (en) 2014-08-08 2015-08-06 Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors

Publications (2)

Publication Number Publication Date
AU2015301014A1 AU2015301014A1 (en) 2017-03-02
AU2015301014B2 true AU2015301014B2 (en) 2021-05-06

Family

ID=55264557

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015301014A Active AU2015301014B2 (en) 2014-08-08 2015-08-06 Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors

Country Status (6)

Country Link
EP (1) EP3177713B1 (enExample)
JP (1) JP6764864B2 (enExample)
AU (1) AU2015301014B2 (enExample)
CA (1) CA2957552C (enExample)
ES (1) ES2822557T3 (enExample)
WO (1) WO2016022805A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149562A2 (en) 2015-03-17 2016-09-22 Omniox, Inc. Modulation of tumor immunity by protein-mediated 02 delivery
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
US11213594B2 (en) 2016-04-29 2022-01-04 Poseida Therapeutics, Inc. Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
EP3519561A1 (en) 2016-09-30 2019-08-07 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
CN110267980A (zh) 2016-10-06 2019-09-20 波赛达治疗公司 诱导型胱天蛋白酶及使用方法
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
US20230241184A1 (en) * 2020-06-23 2023-08-03 Virtech Bio, Inc Compositions and Methods for Treating Hemorrhagic Shock

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
WO2011133635A2 (en) * 2010-04-20 2011-10-27 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
WO2012094679A2 (en) * 2011-01-07 2012-07-12 Vindico NanoBio Technology Inc. Compositions and methods for delivery of high-affinity oxygen binding agents to tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624540D0 (en) * 1996-11-26 1997-01-15 Nycomed Imaging As Compositions
EP1131106B1 (en) * 1998-11-12 2009-06-24 Novolytics Inc. Compositions and methods for producing vascular occlusion
US6946484B2 (en) * 2000-04-26 2005-09-20 Cellegy Pharmaceuticals, Inc. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
CA2459794C (en) * 2001-09-12 2012-08-21 Virexx Medical Corp. Vascular occlusion solid-phase agent with immobilised platelet binding agent
WO2009126705A2 (en) * 2008-04-10 2009-10-15 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy
US9044454B2 (en) * 2010-03-10 2015-06-02 Northwestern University Regulation of microvasculature occlusion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612310A (en) * 1993-05-24 1997-03-18 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
WO2011133635A2 (en) * 2010-04-20 2011-10-27 Vindico NanoBio Technology Inc. Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
WO2012094679A2 (en) * 2011-01-07 2012-07-12 Vindico NanoBio Technology Inc. Compositions and methods for delivery of high-affinity oxygen binding agents to tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LINGE WANG ET AL, "Encapsulation of Biomacromolecules within Polymersomes by Electroporation", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, (2012-09-28), vol. 51, no. 44, doi:10.1002/anie.201204169, ISSN 1433-7851, pages 11122 - 11125 *

Also Published As

Publication number Publication date
ES2822557T3 (es) 2021-05-04
AU2015301014A1 (en) 2017-03-02
JP2017526740A (ja) 2017-09-14
CA2957552A1 (en) 2016-02-11
JP6764864B2 (ja) 2020-10-07
EP3177713B1 (en) 2020-08-05
EP3177713A1 (en) 2017-06-14
CA2957552C (en) 2024-01-16
WO2016022805A1 (en) 2016-02-11
EP3177713A4 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
US20200338361A1 (en) Compositions and methods for inducing nanoparticle-mediated microvascular embolization for tumors
US20200138716A1 (en) Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
EP2661275B1 (en) Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
AU2015301014B2 (en) Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
Dong et al. Enhanced drug delivery by nanoscale integration of a nitric oxide donor to induce tumor collagen depletion
US9421247B2 (en) Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
Forouhari et al. Liposomes: Ideal drug delivery systems in breast cancer
Yamamoto et al. Systemic administration of hemoglobin vesicle elevates tumor tissue oxygen tension and modifies tumor response to irradiation
HK1239746B (en) Compositions and their use for inducing nanoparticle-mediated microvascular embolization of tumors
HK1239746A1 (en) Compositions and their use for inducing nanoparticle-mediated microvascular embolization of tumors
AU2015204358B2 (en) Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
Liu et al. Nano-Based Strategies Aiming at Tumor Microenvironment for Improved Cancer Therapy
Tošić et al. Application of nanomedical technology in breast cancer treatment
Fullagar Nanoencapsulation of bilirubin and its effects on isolated murine pancreatic islet cells

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: POSEIDA THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): VINDICO NANOBIOTECHNOLOGY, LLC

FGA Letters patent sealed or granted (standard patent)